Cover Image
市場調查報告書

葛瑞夫茲氏眼病變:開發中產品分析

Graves' Ophthalmopathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 362364
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
葛瑞夫茲氏眼病變:開發中產品分析 Graves' Ophthalmopathy - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 39 Pages
簡介

本報告提供葛瑞夫茲氏眼病變治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

葛瑞夫茲氏眼病變概要

治療藥的開發

  • 開發中產品的概要

葛瑞夫茲氏眼病變:企業開發中的治療藥

葛瑞夫茲氏眼病變:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

葛瑞夫茲氏眼病變:企業開發中的產品

葛瑞夫茲氏眼病變的治療藥的開發企業

  • Genmab A/S
  • Neothetics, Inc.
  • Novartis AG
  • Yuhan Corporation

葛瑞夫茲氏眼病變:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

葛瑞夫茲氏眼病變:最近的開發平台趨勢

葛瑞夫茲氏眼病變:暫停中的計劃

葛瑞夫茲氏眼病變:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8802IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy - Pipeline Review, H2 2016, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves' ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves'ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 2 and 1 respectively.Graves' Ophthalmopathy.

Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graves' Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graves' Ophthalmopathy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graves' Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Graves' Ophthalmopathy Overview
  • Therapeutics Development
    • Pipeline Products for Graves' Ophthalmopathy - Overview
  • Graves' Ophthalmopathy - Therapeutics under Development by Companies
  • Graves' Ophthalmopathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Graves' Ophthalmopathy - Products under Development by Companies
  • Graves' Ophthalmopathy - Companies Involved in Therapeutics Development
    • Genmab A/S
    • Neothetics Inc
    • Novartis AG
    • Yuhan Corp
  • Graves' Ophthalmopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (fluticasone propionate + salmeterol xinafoate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Graves' Orbitopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teprotumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-BIO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-NCE3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Graves' Ophthalmopathy - Dormant Projects
  • Graves' Ophthalmopathy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease
      • Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Graves' Ophthalmopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Graves' Ophthalmopathy - Pipeline by Genmab A/S, H2 2016
  • Graves' Ophthalmopathy - Pipeline by Neothetics Inc, H2 2016
  • Graves' Ophthalmopathy - Pipeline by Novartis AG, H2 2016
  • Graves' Ophthalmopathy - Pipeline by Yuhan Corp, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Graves' Ophthalmopathy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Graves' Ophthalmopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top